Priming cancer cells for drug resistance: role of the fibroblast niche

Abstract

Conventional and targeted chemotherapies remain integral strategies to treat solid tumors. Despite the large number of anti-cancer drugs available, chemotherapy does not completely eradicate disease. Disease recurrence and the growth of drug resistant tumors remain significant problems in anti-cancer treatment. To develop more effective treatment strategies, it is important to understand the underlying cellular and molecular mechanisms of drug resistance. It is generally accepted that cancer cells do not function alone, but evolve through interactions with the surrounding tumor microenvironment. As key cellular components of the tumor microenvironment, fibroblasts regulate the growth and progression of many solid tumors. Emerging studies demonstrate that fibroblasts secrete a multitude of factors that enable cancer cells to become drug resistant. This review will explore how fibroblast secretion of soluble factors act on cancer cells to enhance cancer cell survival and cancer stem cell renewal, contributing to the development of drug resistant cancer.

Key words： fibroblasts; tumor recurrence; drug resistance; cell survival; stem cells; tumor dormancy

Acknowledgements

This work is supported by NIH/NCI (R01CA172764) and American Cancer Society (RSG-13-183-01-CSM) to NC. We apologize for any studies that were unintentionally omitted from this review.

Compliance with ethics guidelines

The authors declare no conflict of interest.

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

1 AblettM P O B C, SimsA H, FarnieG, ClarkeR B (2013). A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity. OncotargetEpub.

2 AdamsD J, KnickV C (1995). P-glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine). Invest New Drugs, 13(1): 13–21

PMID

3 AddadiY, MoskovitsN, GranotD, LozanoG, CarmiY, ApteR N, NeemanM, OrenM (2010). p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res, 70(23): 9650–9658

PMID

4 Aguirre-GhisoJ A, OssowskiL, RosenbaumS K (2004). Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res, 64(20): 7336–7345

PMID

5 AhnS, ChoJ, SungJ, LeeJ E, NamS J, KimK M, ChoE Y (2012). The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol, 33(5): 1573–1580

PMID

6 AishimaS, TaguchiK, TerashiT, MatsuuraS, ShimadaM, and TsuneyoshiM (2003). Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc16 (10), 1019–1027.

7 AllavenaP, GermanoG, MarchesiF, MantovaniA (2011). Chemokines in cancer related inflammation. Exp Cell Res, 317(5): 664–673

PMID

8 AllinenM, BeroukhimR, CaiL, BrennanC, Lahti-DomeniciJ, HuangH, PorterD, HuM, ChinL, RichardsonA, SchnittS, SellersW R, PolyakK (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1): 17–32

PMID

9 AmarS, RoyV, PerezE A (2009). Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res Treat, 114(3): 413–422

PMID

10 AnastasJ N, MoonR T (2013). WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer, 13(1): 11–26

PMID

11 AstsaturovI, RatushnyV, SukhanovaA, EinarsonM B, BagnyukovaT, ZhouY, DevarajanK, SilvermanJ S, TikhmyanovaN, SkobelevaN, PecherskayaA, NastoR E, SharmaC, JablonskiS A, SerebriiskiiI G, WeinerL M, GolemisE A (2010). Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal, 3(140): ra67

PMID

12 AyalaG, TuxhornJ A, WheelerT M, FrolovA, ScardinoP T, OhoriM, WheelerM, SpitlerJ, RowleyD R (2003). Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res, 9(13): 4792–4801

PMID

13 BalkwillF R (2012). The chemokine system and cancer. J Pathol, 226(2): 148–157

PMID

14 BalkwillF R, MantovaniA (2012). Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol, 22(1): 33–40

PMID

15 BaoL, HaqueA, JacksonK, HazariS, MorozK, JetlyR, DashS (2011). Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol, 178(2): 838–852

PMID

16 BaoS, OuyangG, BaiX, HuangZ, MaC, LiuM, ShaoR, AndersonR M, RichJ N, WangX F (2004). Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell, 5(4): 329–339

PMID

17 BarilP, GangeswaranR, MahonP C, CauleeK, KocherH M, HaradaT, ZhuM, KalthoffH, Crnogorac-JurcevicT, and LemoineN R (2007). Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene26(14), 2082–2094

18 BielenH, HouartC (2014). The Wnt Cries Many: Wnt regulation of neurogenesis through tissue patterning, proliferation and asymmetric cell division. Dev Neurobiol: n/a

PMID

19 BinaschiM, SupinoR, GambettaR A, GiacconeG, ProsperiE, CapranicoG, CataldoI, ZuninoF (1995). MRP gene overexpression in a human doxorubicin-resistant SCLC cell line: alterations in cellular pharmacokinetics and in pattern of cross-resistance. Int J Cancer, 62(1): 84–89

PMID

20 BrellierF, Chiquet-EhrismannR (2012). How do tenascins influence the birth and life of a malignant cell? J Cell Mol Med, 16(1): 32–40

PMID

21 BrewsterA M, HortobagyiG N, BroglioK R, KauS W, Santa-MariaC A, ArunB, BuzdarA U, BooserD J, ValeroV, BondyM, EstevaF J (2008). Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst, 100(16): 1179–1183

PMID

22 BrunnerA, MayerlC, TzankovA, VerdorferI, TschörnerI, RogatschH, MikuzG (2004). Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol, 57(9): 927–931

PMID

23 BuckM B, PfizenmaierK, KnabbeC (2004). Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol, 18(7): 1643–1657

PMID

24 BurgerJ A, and KippsT J (2006). CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 107(5): 1761–1767

25 BusamK J (2011). Desmoplastic melanoma. Clin Lab Med, 31(2): 321–330

PMID

26 BuyukbayramH, ArslanA (2002). Value of tenascin-C content and association with clinicopathological parameters in uterine cervical lesions. Int J Cancer, 100(6): 719–722

PMID

27 CampsJ L, ChangS M, HsuT C, FreemanM R, HongS J, ZhauH E, von EschenbachA C, ChungL W (1990). Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci USA, 87(1): 75–79

PMID

28 CecchiF, RabeD C, BottaroD P (2010). Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer, 46(7): 1260–1270

PMID

29 ChaoC, CarmicalJ R, IvesK L, WoodT G, AronsonJ F, GomezG A, DjukomC D, HellmichM R (2012). CD133+ colon cancer cells are more interactive with the tumor microenvironment than CD133- cells. Lab Invest, 92(3): 420–436

PMID

30 ChenJ T, HuangC Y, ChiangY Y, ChenW H, ChiouS H, ChenC Y, ChowK C (2008). HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. Am J Respir Cell Mol Biol, 38(5): 559–565

PMID

31 ChenS S, LeeL (1984). Prognostic significance of morphology of tumor and retroperitoneal lymph nodes in epithelial carcinoma of the ovary. II. Correlation with survival. Gynecol Oncol, 18(1): 94–99

PMID

32 ChoiK U, YunJ S, LeeI H, HeoS C, ShinS H, JeonE S, ChoiY J, SuhD S, YoonM S, KimJ H (2011). Lysophosphatidic acid-induced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer. Int J Cancer, 128(2): 332–342

PMID

33 CohenM, Marchand-AdamS, Lecon-MalasV, Marchal-SommeJ, BouttenA, DurandG, CrestaniB, DehouxM (2006). HGF synthesis in human lung fibroblasts is regulated by oncostatin M. Am J Physiol Lung Cell Mol Physiol, 290(6): L1097–L1103

PMID

34 CohenS J, AlpaughR K, PalazzoI, MeropolN J, RogatkoA, XuZ, HoffmanJ P, WeinerL M, ChengJ D (2008). Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas, 37(2): 154–158

35 ConklinM W, KeelyP J (2012). Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adhes Migr, 6(3): 249–260

PMID

36 ContiI, RollinsB J (2004). CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol, 14(3): 149–154

PMID

37 DačevićM, IsakovićA, Podolski-RenićA, IsakovićA M, StankovićT, MiloševićZ, RakićL, RuždijićS, PešićM (2013). Purine nucleoside analog—sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines. PLoS ONE, 8(1): e54044

PMID

38 DalyA J, McIlreaveyL, IrwinC R (2008). Regulation of HGF and SDF-1 expression by oral fibroblasts—implications for invasion of oral cancer. Oral Oncol, 44(7): 646–651

PMID

39 de BoerR A, van VeldhuisenD J, GansevoortR T, Muller KoboldA C, van GilstW H, HillegeH L, BakkerS J, van der HarstP (2012). The fibrosis marker galectin-3 and outcome in the general population. J Intern Med, 272(1): 55–64

PMID

40 de BoussacH, OrbánT I, VáradyG, TihanyiB, BacquetC, BrózikA, VáradiA, SarkadiB, ArányiT (2012). Stimulus-induced expression of the ABCG2 multidrug transporter in HepG2 hepatocarcinoma model cells involves the ERK1/2 cascade and alternative promoters. Biochem Biophys Res Commun, 426(2): 172–176

PMID

41 De WeverO, NguyenQ D, Van HoordeL, BrackeM, BruyneelE, GespachC, MareelM (2004). Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J, 18(9): 1016–1018

PMID

42 DeanM (2009). ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia, 14(1): 3–9

PMID

43 DengB, HuangW, TanQ Y, FanX Q, JiangY G, LiuL, ZhongY Y, LiangY G, WangR W (2011). Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum. Mol Diagn Ther, 15(1): 31–40

PMID

44 DeVitaV T Jr, ChuE (2008). A history of cancer chemotherapy. Cancer Res, 68(21): 8643–8653

PMID

45 DiahS K, SmithermanP K, AldridgeJ, VolkE L, SchneiderE, TownsendA J, MorrowC S (2001). Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res, 61(14): 5461–5467

PMID

46 DiazL A, Jr., WilliamsR T, WuJ, KindeI, HechtJ R, BerlinJ, AllenB, BozicI, ReiterJ G, NowakM A, KinzlerK W, OlinerK S, and VogelsteinB (2012). The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature486(7404), 537–540.

47 DomanskaU M, Timmer-BosschaH, NagengastW B, Oude MunninkT H, KruizingaR C, AnaniasH J, KliphuisN M, HulsG, De VriesE G, de JongI J, WalenkampA M (2012). CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia, 14(8): 709–718

48 DubrovskaA, ElliottJ, SalamoneR J, TelegeevG D, StakhovskyA E, SchepotinI B, YanF, WangY, BouchezL C, KularatneS A, WatsonJ, TrussellC, ReddyV A, ChoC Y, SchultzP G (2012). CXCR4 expression in prostate cancer progenitor cells. PLoS ONE, 7(2): e31226

PMID

49 EarpH S, DawsonT L, LiX, YuH (1995). Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat, 35(1): 115–132

PMID

50 EmotoK, YamadaY, SawadaH, FujimotoH, UenoM, TakayamaT, KamadaK, NaitoA, HiraoS, and NakajimaY (2001). Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer, 92(6): 1419–1426

51 ErbasB, ProvenzanoE, ArmesJ, GertigD (2006). The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat, 97(2): 135–144

PMID

52 EymanD, DamodarasamyM, PlymateS R, ReedM J (2009). CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis. J Cell Physiol, 220(2): 376–381

PMID

53 FangW B, JokarI, ZouA, LambertD, DendukuriP, ChengN (2012). CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem, 287(43): 36593–36608

PMID

54 FeigC, JonesJ O, KramanM, WellsR J, DeonarineA, ChanD S, ConnellC M, RobertsE W, ZhaoQ, CaballeroO L, TeichmannS A, JanowitzT, JodrellD I, TuvesonD A, FearonD T (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA, 110(50): 20212–20217

PMID

55 FlahertyK T, PuzanovI, KimK B, RibasA, McArthurG A, SosmanJ A, O’DwyerP J, LeeR J, GrippoJ F, NolopK, ChapmanP B (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 363(9): 809–819

PMID

56 FlemingJ M, MillerT C, KidackiM, GinsburgE, StueltenC H, StewartD A, TroesterM A, VonderhaarB K (2012). Paracrine interactions between primary human macrophages and human fibroblasts enhance murine mammary gland humanization in vivo. Breast Cancer Res, 14(3): R97

PMID

57 FoleyJ, NickersonN K, NamS, AllenK T, GilmoreJ L, NephewK P, RieseD J 2nd (2010). EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol, 21(9): 951–960

PMID

58 FujimotoH, SangaiT, IshiiG, IkeharaA, NagashimaT, MiyazakiM, OchiaiA (2009). Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer, 125(6): 1276–1284

PMID

59 Fukunaga-KalabisM, MartinezG, NguyenT K, KimD, Santiago-WalkerA, RoeschA, and HerlynM (2010). Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene, 29(46): 6115–6124

60 GaoC F, Vande WoudeG F (2005). HGF/SF-Met signaling in tumor progression. Cell Res, 15(1): 49–51

PMID

61 GillanL, MateiD, FishmanD A, GerbinC S, KarlanB Y, ChangD D (2002). Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res, 62(18): 5358–5364

PMID

62 GoldbergR M (2006). Intensive surveillance after stage II or III colorectal cancer: is it worth it? J Clin Oncol, 24(3): 330–331

PMID

63 GongX G, LvY F, LiX Q, XuF G, MaQ Y (2010). Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol Pharm Bull, 33(8): 1261–1267

PMID

64 GuirouilhJ, CastroviejoM, BalabaudC, DesmouliereA, RosenbaumJ (2000). Hepatocarcinoma cells stimulate hepatocyte growth factor secretion in human liver myofibroblasts. Int J Oncol, 17(4): 777–781

PMID

65 GuptaV, BassiD E, SimonsJ D, DevarajanK, Al-SaleemT, UzzoR G, CukiermanE (2011). Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS ONE, 6(6): e21494

PMID

66 HasebeT, MukaiK, TsudaH, OchiaiA (2000). New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus. Pathol Int, 50(4): 263–272

PMID

67 HeidelbergerC, ChaudhuriN K, DannebergP, MoorenD, GriesbachL, DuschinskyR, SchnitzerR J, PlevenE, ScheinerJ (1957). Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature179(4561), 663–666

68 HembruffS L, JokarI, YangL, ChengN (2010). Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and-independent mechanisms. Neoplasia, 12(5): 425–433

69 HermannP C, HuberS L, HerrlerT, AicherA, EllwartJ W, GubaM, BrunsC J, HeeschenC (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1(3): 313–323

PMID

70 HerreraM, HerreraA, DomínguezG, SilvaJ, GarcíaV, GarcíaJ M, GómezI, SoldevillaB, MuñozC, ProvencioM, Campos-MartinY, García de HerrerosA, CasalI, BonillaF, PeñaC (2013). Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci, 104(4): 437–444

PMID

71 HidalgoM (2010). Pancreatic cancer. N Engl J Med, 362(17): 1605–1617

PMID

72 HolohanC, Van SchaeybroeckS, LongleyD B, JohnstonP G (2013). Cancer drug resistance: an evolving paradigm. Nat Rev Cancer, 13(10): 714–726

PMID

73 HongL Z, WeiX W, ChenJ F, ShiY (2013). Overexpression of periostin predicts poor prognosis in non-small cell lung cancer. Oncol Lett, 6(6):1595–1603

74 Ibarra-DrendallC, DietzeE C, SeewaldtV L (2011). Metabolic syndrome and breast cancer risk: Is there a role for metformin? Current Breast Cancer Rep, 3(3): 142–150

75 IlmonenS, JahkolaT, TurunenJ P, MuhonenT, Asko-SeljavaaraS (2004). Tenascin-C in primary malignant melanoma of the skin. Histopathology, 45(4): 405–411

76 JahkolaT, ToivonenT, VirtanenI, von SmittenK, NordlingS, von BoguslawskiK, HaglundC, NevanlinnaH, BlomqvistC (1998). Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer, 78(11): 1507–1513

PMID

77 JinJ, HuangM, WeiH L, LiuG T (2002). Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J Gastroenterol, 8(6): 1029–1034

PMID

78 KahnN, MeisterM, EberhardtR, MuleyT, SchnabelP A, BenderC, JohannesM, KeitelD, SultmannH, HerthF J, KunerR (2012). Early detection of lung cancer by molecular markers in endobronchial epithelial-lining fluid. J Thoracic Oncol, 7(6): 1001–1008

79 KalluriR, ZeisbergM (2006). Fibroblasts in cancer. Nat Rev Cancer, 6(5): 392–401

PMID

80 KasedaK, IshiiG, AokageK, TakahashiA, KuwataT, HishidaT, YoshidaJ, KohnoM, NagaiK, OchiaiA (2013). Identification of intravascular tumor microenvironment features predicting the recurrence of pathological stage I lung adenocarcinoma. Cancer Sci, 104(9): 1262–1269

PMID

81 KawashiriS, TanakaA, NoguchiN, HaseT, NakayaH, OharaT, KatoK, YamamotoE (2009). Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck, 31(10): 1346–1353

PMID

82 KeizerH G, SchuurhuisG J, BroxtermanH J, LankelmaJ, SchoonenW G, van RijnJ, PinedoH M, JoenjeH (1989). Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res, 49(11): 2988–2993

PMID

83 KempL E, MulloyB, GherardiE (2006). Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. Biochem Soc Trans, 34(Pt 3): 414–417

PMID

84 KhunamornpongS, LekawanvijitS, SettakornJ, SukpanK, SuprasertP, SiriaunkgulS (2013). Prognostic model in patients with early-stage squamous cell carcinoma of the uterine cervix: a combination of invasive margin pathological characteristics and lymphovascular space invasion. Asian Pac J Cancer Prev, 14(11): 6935–6940

PMID

85 KiiI, NishiyamaT, LiM, MatsumotoK, SaitoM, AmizukaN, KudoA (2010). Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem, 285(3): 2028–2039

PMID

86 KitanoH, KageyamaS, HewittS M, HayashiR, DokiY, OzakiY, FujinoS, TakikitaM, KuboH, FukuokaJ (2010). Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch Pathol Lab Med, 134(10): 1520–1527

PMID

87 KojimaM, NakajimaK, IshiiG, SaitoN, OchiaiA (2010). Peritoneal elastic laminal invasion of colorectal cancer: the diagnostic utility and clinicopathologic relationship. Am J Surg Pathol, 34(9): 1351–1360

PMID

88 KreuzalerP, WatsonC J (2012). Killing a cancer: what are the alternatives? Nat Rev Cancer, 12(6): 411–424

PMID

89 KuciaM, JankowskiK, RecaR, WysoczynskiM, BanduraL, AllendorfD J, ZhangJ, RatajczakJ, RatajczakM Z (2004). CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol, 35(3): 233–245

PMID

90 KwonY, SmithB D, ZhouY, KaufmanM D, GodwinA K (2013). Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment. Oncogene,

91 LariS A, KuererH M (2011). Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer, 2: 232–261

PMID

92 LeeS H, KimH, HwangJ H, LeeH S, ChoJ Y, YoonY S, HanH S (2012). Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients. Pathol Int, 62(3): 167–175

PMID

93 LemmonM A, and SchlessingerJ (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7): 1117–1134

94 LengauerC, KinzlerK W, and VogelsteinB (1998). Genetic instabilities in human cancers. Nature, 396(6712): 643–649

95 LevinaV, MarrangoniA M, DeMarcoR, GorelikE, LokshinA E (2008). Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE, 3(8): e3077

PMID

96 LhomméC, JolyF, WalkerJ L, LissoniA A, NicolettoM O, ManikhasG M, BaekelandtM M, GordonA N, FracassoP M, MietlowskiW L, JonesG J, DuganM H (2008). Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol, 26(16): 2674–2682

PMID

97 LiL, DragulevB, ZigrinoP, MauchC, FoxJ W (2009). The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo. Int J Cancer, 125(8): 1796–1804

PMID

98 LiM, LiC, LiD, XieY, ShiJ, LiG, GuanY, LiM, ZhangP, PengF, XiaoZ, ChenZ (2012). Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma. Clin Exp Metastasis, 29(8): 865–877

PMID

99 LiaoD, LuoY, MarkowitzD, XiangR, ReisfeldR A (2009). Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE, 4(11): e7965

PMID

100 LimK P, CirilloN, HassonaY, WeiW, ThurlowJ K, CheongS C, PitiyageG, ParkinsonE K, PrimeS S (2011). Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma. J Pathol, 223(4): 459–469

PMID

101 LiuR, LiJ, XieK, ZhangT, LeiY, ChenY, ZhangL, HuangK, WangK, WuH, WuM, NiceE C, HuangC, WeiY (2013). FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res, 73(19): 5926–5935

PMID

102 LoebingerM R, GiangrecoA, GrootK R, PrichardL, AllenK, SimpsonC, BazleyL, NavaniN, TibrewalS, DaviesD, JanesS M (2008). Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br J Cancer, 98(2): 380–387

PMID

103 LottiF, JarrarA M, PaiR K, HitomiM, LathiaJ, MaceA, GanttG A Jr, SukhdeoK, DeVecchioJ, VasanjiA, LeahyP, HjelmelandA B, KaladyM F, RichJ N (2013). Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med, 210(13): 2851–2872

PMID

104 LuY, ChenQ, CoreyE, XieW, FanJ, MizokamiA, ZhangJ (2009). Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2): 161–169

PMID

105 LuY, XiaoG, GalsonD L, NishioY, MizokamiA, KellerE T, YaoZ, ZhangJ (2007). PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer, 121(4): 724–733

PMID

106 LvY, WangW, JiaW D, SunQ K, LiJ S, MaJ L, LiuW B, ZhouH C, GeY S, YuJ H, XiaH H, XuG L (2013). High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma. Med Oncol, 30(1): 385

PMID

107 MacDonaldB T, TamaiK, HeX (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 17(1): 9–26

PMID

108 MalanchiI, Santamaria-MartinezA, SusantoE, PengH, LehrH A, DelaloyeJ F, HuelskenJ (2012). Interactions between cancer stem cells and their niche govern metastatic colonization. Nature, 481(7379): 85–89

109 MalofeevaE V, DomanitskayaN, GudimaM, Hopper-BorgeE A (2012). Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res, 72(24): 6457–6467

PMID

110 MarshD, SuchakK, MoutasimK A, VallathS, HopperC, JerjesW, UpileT, KalavrezosN, VioletteS M, WeinrebP H, ChesterK A, ChanaJ S, MarshallJ F, HartI R, HackshawA K, PiperK, ThomasG J (2011). Stromal features are predictive of disease mortality in oral cancer patients. J Pathol, 223(4): 470–481

PMID

111 MasuokaM, ShiraishiH, OhtaS, SuzukiS, ArimaK, AokiS, TodaS, InagakiN, KuriharaY, HayashidaS, TakeuchiS, KoikeK, OnoJ, NoshiroH, FurueM, ConwayS J, NarisawaY, IzuharaK (2012). Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest, 122(7): 2590–2600

PMID

112 MertensJ C, FingasC D, ChristensenJ D, SmootR L, BronkS F, WerneburgN W, GustafsonM P, DietzA B, RobertsL R, SiricaA E, GoresG J (2013). Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res, 73(2): 897–907

PMID

113 Mhawech-FaucegliaP, WangD, SamraoD, KimG, LawrensonK, MenesesT, LiuS, YessaianA, PejovicT (2013). Clinical implications of marker expression of carcinoma-associated Fibroblasts (CAFs) in patients with epithelial ovarian carcinoma after treatment with neoadjuvant chemotherapy. Cancer Microenviron,

PMID

114 MillwardM J, CantwellB M, MunroN C, RobinsonA, CorrisP A, HarrisA L (1993). Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer, 67(5): 1031–1035

PMID

115 MuellerL, von SeggernL, SchumacherJ, GoumasF, WilmsC, BraunF, BroeringD C (2010). TNF-alpha similarly induces IL-6 and MCP-1 in fibroblasts from colorectal liver metastases and normal liver fibroblasts. Biochem Biophys Res Commun, 397(3): 586–591

PMID

116 NaldiniL, WeidnerK M, VignaE, GaudinoG, BardelliA, PonzettoC, NarsimhanR P, HartmannG, ZarnegarR, MichalopoulosG K, et al (1991). Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J, 10(10): 2867–2878

PMID

117 NaumovG N, TownsonJ L, MacDonaldI C, WilsonS M, BramwellV H, GroomA C, ChambersA F (2003). Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat, 82(3): 199–206

PMID

118 NicoloG, SalviS, OliveriG, BorsiL, CastellaniP, ZardiL (1990). Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer. Cell Differ Dev, 32(3): 401–408

119 NuzzoP V, RubagottiA, ZinoliL, RicciF, SalviS, BoccardoS, BoccardoF (2012). Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death. BMC Cancer, 12(1): 625

PMID

120 O’ConnellJ T, SugimotoH, CookeV G, MacDonaldB A, MehtaA I, LeBleuV S, DewarR, RochaR M, BrentaniR R, ResnickM B, NeilsonE G, ZeisbergM, KalluriR (2011). VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA, 108(38): 16002–16007

PMID

121 OguriT, OzasaH, UemuraT, BesshoY, MiyazakiM, MaenoK, MaedaH, SatoS, UedaR (2008). MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther, 7(5): 1150–1155

PMID

122 OhiraS, SasakiM, HaradaK, SatoY, ZenY, IsseK, KozakaK, IshikawaA, OdaK, NimuraY, NakanumaY (2006). Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol, 168(4): 1155–1168

PMID

123 OhnishiT, DaikuharaY (2003). Hepatocyte growth factor/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol, 48(12): 797–804

PMID

124 OhnoY, IzumiM, YoshiokaK, OhoriM, YonouH, TachibanaM (2008). Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma. Oncol Rep, 20(3): 511–516

PMID

125 OlumiA F, GrossfeldG D, HaywardS W, CarrollP R, TlstyT D, CunhaG R (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res, 59(19): 5002–5011

PMID

126 OrendG, Chiquet-EhrismannR (2006). Tenascin-C induced signaling in cancer. Cancer Lett, 244(2): 143–163

PMID

127 OrimoA, GuptaP B, SgroiD C, Arenzana-SeisdedosF, DelaunayT, NaeemR, CareyV J, RichardsonA L, WeinbergR A (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3): 335–348

128 OskarssonT, AcharyyaS, ZhangX H, VanharantaS, TavazoieS F, MorrisP G, DowneyR J, Manova-TodorovaK, BrogiE, MassaguéJ (2011). Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med, 17(7): 867–874

PMID

129 OstmanA, AugstenM (2009). Cancer-associated fibroblasts and tumor growth—bystanders turning into key players. Curr Opin Genet Dev, 19(1): 67–73

PMID

130 ParrC, JiangW G (2001). Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int J Oncol, 19(4): 857–863

PMID

131 PaulssonJ, SjöblomT, MickeP, PonténF, LandbergG, HeldinC H, BerghJ, BrennanD J, JirströmK, OstmanA (2009). Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol, 175(1): 334–341

PMID

132 PeledA, and TavorS (2013). Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics3(1), 34–39.

133 PezzoloA, ParodiF, MarimpietriD, RaffaghelloL, CoccoC, PistorioA, MosconiM, GambiniC, CilliM, DeaglioS, MalavasiF, PistoiaV (2011). Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res, 21(10): 1470–1486

PMID

134 PolanskaU M, OrimoA (2013). Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol, 228(8): 1651–1657

PMID

135 PolyakK, KalluriR (2010). The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol, 2(11): a003244

PMID

136 QianB Z, LiJ, ZhangH, KitamuraT, ZhangJ, CampionL R, KaiserE A, SnyderL A, and PollardJ W (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature475(7355), 222–225.

137 QianD Z, RademacherB L, PittsenbargerJ, HuangC Y, MyrthueA, HiganoC S, GarzottoM, NelsonP S, and BeerT M (2010). CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate, 70(4): 433–442

138 RobertsP J, and DerC J (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26(22): 3291–3310

139 RocaH, VarsosZ, PientaK J (2008). CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem, 283(36): 25057–25073

PMID

140 RoninsonI B (2003). Tumor cell senescence in cancer treatment. Cancer Res, 63(11): 2705–2715

PMID

141 SamaratungaH, FairweatherP, PurdieD (2005). Significance of stromal reaction patterns in invasive urothelial carcinoma. Am J Clin Pathol, 123(6): 851–857

PMID

142 SankalaH M, HaitN C, PaughS W, ShidaD, LépineS, ElmoreL W, DentP, MilstienS, SpiegelS (2007). Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res, 67(21): 10466–10474

PMID

143 SchoppmannS F, JeschB, RieglerM F, MaroskeF, SchwameisK, JomrichG, BirnerP (2013). Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis, 30(4): 441–446

PMID

144 SeslarS P, NakamuraT, ByersS W (1993). Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors. Cancer Res, 53(6): 1233–1238

PMID

145 ShimaoY, NabeshimaK, InoueT, KoonoM (1999). Role of fibroblasts in HGF/SF-induced cohort migration of human colorectal carcinoma cells: fibroblasts stimulate migration associated with increased fibronectin production via upregulated TGF-beta1. Int J Cancer, 82(3): 449–458

PMID

146 ShindeA V, FrangogiannisN G (2013). Fibroblasts in myocardial infarction: A role in inflammation and repair. J Mol Cell Cardiol,

PMID

147 SiegsmundM J, KreuklerC, SteidlerA, NebeT, KöhrmannK U, AlkenP (1997). Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol Res, 25(1): 35–41

PMID

148 SilzleT, KreutzM, DoblerM A, BrockhoffG, KnuechelR, Kunz-SchughartL A (2003). Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur J Immunol, 33(5): 1311–1320

PMID

149 SmithN Z (2012). Treating metastatic breast cancer with systemic chemotherapies: current trends and future perspectives. Clin J Oncol Nurs, 16(2): E33–E43

PMID

150 SoonP S, KimE, PonC K, GillA J, MooreK, SpillaneA J, BennD E, BaxterR C (2013). Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr Relat Cancer, 20(1): 1–12

PMID

151 StokerM, GherardiE, PerrymanM, GrayJ (1987). Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature, 327(6119): 239–242

152 StokerM, PerrymanM (1985). An epithelial scatter factor released by embryo fibroblasts. J Cell Sci, 77: 209–223

PMID

153 StraussmanR, MorikawaT, SheeK, Barzily-RokniM, QianZ R, DuJ, DavisA, MongareM M, GouldJ, FrederickD T, CooperZ A, ChapmanP B, SolitD B, RibasA, LoR S, FlahertyK T, OginoS, WargoJ A, GolubT R (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 487(7408): 500–504

154 StupackD G, ChereshD A (2002). Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci, 115(Pt 19): 3729–3738

PMID

155 SturmI, BosanquetA G, HermannS, GünerD, DörkenB, DanielP T (2003). Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ, 10(4): 477–484

PMID

156 SunY, CampisiJ, HiganoC, BeerT M, PorterP, ColemanI, TrueL, NelsonP S (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med, 18(9): 1359–1368

PMID

157 TakeuchiK, ItoF (2011). Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull, 34(12): 1774–1780

PMID

158 TaylorC W, DaltonW S, ParrishP R, GleasonM C, BellamyW T, ThompsonF H, RoeD J, TrentJ M (1991). Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer, 63(6): 923–929

PMID

159 TegzeB, SzállásiZ, HaltrichI, PénzváltóZ, TóthZ, LikóI, GyorffyB (2012). Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS ONE, 7(2): e30804

PMID

160 ThomasD, VadasM, LopezA (2004). Regulation of haematopoiesis by growth factors- emerging insights and therapies. Expert Opin Biol Ther, 4(6): 869–879

PMID

161 TjomslandV, NiklassonL, SandströmP, BorchK, DruidH, Bratth–llC, MessmerD, LarssonM, SpångeusA (2011). The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol, 2011: 212810

PMID

162 TorresS, BartoloméR A, MendesM, BarderasR, Fernandez-AceñeroM J, Peláez-GarcíaA, PeñaC, Lopez-LucendoM, Villar-VázquezR, de HerrerosA G, BonillaF, CasalJ I (2013). Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res, 19(21): 6006–6019

PMID

163 TsujinoT, SeshimoI, YamamotoH, NganC Y, EzumiK, TakemasaI, IkedaM, SekimotoM, MatsuuraN, MondenM (2007). Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res, 13(7): 2082–2090

PMID

164 TsuyadaA, ChowA, WuJ, SomloG, ChuP, LoeraS, LuuT, LiA X, WuX, YeW, ChenS, ZhouW, YuY, WangY Z, RenX, LiH, ScherleP, KurokiY, WangS E (2012). CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res, 72(11): 2768–2779

PMID

165 UchidaD, KawamataH, OmoteharaF, NakashiroKi, Kimura-YanagawaT, HinoS, BegumN M, HoqueM O, YoshidaH, SatoM, FujimoriT (2001). Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer, 93(4): 489–496

PMID

166 van LeendersG J, SookhlallR, TeubelW J, de RidderC M, RenemanS, SacchettiA, VissersK J, van WeerdenW, JensterG (2011). Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS ONE, 6(11): e26753

PMID

167 VermeulenL, De Sousa E MeloF, van der HeijdenM, CameronK, de JongJ H, BorovskiT, TuynmanJ B, TodaroM, MerzC, RodermondH, SprickM R, KemperK, RichelD J, StassiG, MedemaJ P (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol, 12(5): 468–476

PMID

168 WangB, LiuK, LinH Y, BellamN, LingS, LinW C (2010). 14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol Cell Biol, 30(6): 1508–1527

PMID

169 WangP, NishitaniM A, TanimotoS, KishimotoT, FukumoriT, TakahashiM, and KanayamaH O (2007). Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology, 69(4): 780–784

170 WangQ, FielM I, BlankS, LuanW, KadriH, KimK W, ManizateF, RosenblattA G, LabowD M, SchwartzM E, HiotisS P (2013). Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer, 109(3): 573–581

PMID

171 WangW, LiQ, YamadaT, MatsumotoK, MatsumotoI, OdaM, WatanabeG, KayanoY, NishiokaY, SoneS, YanoS (2009). Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res, 15(21): 6630–6638

PMID

172 WartenbergM, FreyC, DiedershagenH, RitgenJ, HeschelerJ, SauerH (1998). Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int J Cancer, 75(6): 855–863

PMID

173 WhiteG E, IqbalA J, GreavesD R (2013). CC chemokine receptors and chronic inflammation—therapeutic opportunities and pharmacological challenges. Pharmacol Rev, 65(1): 47–89

PMID

174 WilsonK J, MillC, LambertS, BuchmanJ, WilsonT R, Hernandez-GordilloV, GalloR M, AdesL M, SettlemanJ, RieseD J 2nd (2012a). EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors, 30(2): 107–116

PMID

175 WilsonT R, FridlyandJ, YanY, PenuelE, BurtonL, ChanE, PengJ, LinE, WangY, SosmanJ, RibasA, LiJ, MoffatJ, SutherlinD P, KoeppenH, MerchantM, NeveR, and SettlemanJ (2012b). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 487(7408): 505–509

176 WishartG C, BissettD, PaulJ, JodrellD, HarnettA, HabeshawT, KerrD J, MachamM A, SoukopM, LeonardR C, et al (1994). Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol, 12(9): 1771–1777

PMID

177 WongM P, CheungK N, YuenS T, FuK H, ChanA S, LeungS Y, ChungL P (1998). Monocyte chemoattractant protein-1 (MCP-1) expression in primary lymphoepithelioma-like carcinomas (LELCs) of the lung. J Pathol, 186(4): 372–377

PMID

178 WuK J (2011). Direct activation of Bmi1 by Twist1: implications in cancer stemness, epithelial-mesenchymal transition, and clinical significance. Chang Gung Med J, 34(3): 229–238

PMID

179 WuM H, HongH C, HongT M, ChiangW F, JinY T, ChenY L (2011). Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res, 17(6): 1306–1316

PMID

180 XiongJ, BalciogluH E, DanenE H (2013). Integrin signaling in control of tumor growth and progression. Int J Biochem Cell Biol, 45(5): 1012–1015

PMID

181 XuD, XuH, RenY, LiuC, WangX, ZhangH, LuP (2012). Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS ONE, 7(10): e46670

PMID

182 YamadaT, MatsumotoK, WangW, LiQ, NishiokaY, SekidoY, SoneS, YanoS (2010). Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res, 16(1): 174–183

PMID

183 YasunagaM, YamasakiF, TokunagaO, IwasakaT (2003). Endometrial carcinomas with lymph node involvement: novel histopathologic factors for predicting prognosis. Int J Gynecol Pathol, 22(4): 341–346

PMID

184 YoshidaS, HaradaT, IwabeT, TaniguchiF, FujiiA, SakamotoY, YamauchiN, ShiotaG, TerakawaN (2002). Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances growth and invasion of endometrial cancer. J Clin Endocrinol Metab, 87(5): 2376–2383

PMID

185 YuS, XiaS, YangD, WangK, YehS, GaoZ, ChangC (2013). Androgen receptor in human prostate cancer-associated fibroblasts promotes prostate cancer epithelial cell growth and invasion. Med Oncol, 30(3): 674

PMID

186 ZhangJ, YangP L, GrayN S (2009). Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer, 9(1): 28–39

PMID